

1 **Prevalence and effect of bacterial co-infections on clinical outcomes in hospitalized**
2 **COVID-19 patients at a tertiary care centre of India**

3

4 Ashutosh Pathak¹, Sweta Singh¹, Sanjay Singh¹, Sangram Singh Patel¹, Nida Fatima¹, Atul
5 Garg¹, Ujjala Ghoshal^{1*}, Chinmoy Sahu^{1*}

6 Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences,
7 Lucknow, India¹.

8

9

10

11

12

13 *Corresponding authors

14 **Running title:** Bacterial co-infections in COVID-19.

15

16

17 Correspondence

18 Dr. Chinmoy Sahu

19 sahu.chinmoy@gmail.com

20

21

22

23

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 **Background:** Bacterial co-infections are a leading cause of morbidity and mortality during
28 viral infections including COVID-19. Systematic testing of COVID-19 patients having
29 bacterial co-infections is essential to select the correct antibiotic for treatment in order to
30 reduce mortality and also prevent spread of antimicrobial resistance (AMR). The present
31 study aims to evaluate the prevalence, demographic parameters, antibiotic sensitivity patterns
32 and outcomes in hospitalized COVID-19 patients with bacterial co-infections.

33 **Methods:** A total of 1019 COVID-19 patients were selected for the study. We analyzed the
34 prevalence, antibiotic sensitivity pattern and clinical outcomes in COVID-19 patients having
35 bacterial co-infections.

36 **Results:** Out of a total 1019 COVID-19 patients screened, 5.2% of patients demonstrated
37 clinical signs of bacterial co-infection. Bacteremia was found in majority of the patients
38 followed by respiratory and urinary infections. *Escherichia coli*, *Pseudomonas aeruginosa*
39 and *Klebsiella spp.* were most common isolates among the Gram-negative and Coagulase-
40 negative Staphylococci (CONS) and *Staphylococcus aureus* among the Gram-positive
41 bacterial infections. Antibiotic sensitivity profiling revealed that colistin, imipenem and
42 fosfomycin were the most effective drugs against the Gram-negative isolates while
43 vancomycin, teicoplanin and doxycycline against the Gram-positive isolates. Analysis of
44 clinical outcomes revealed that the mortality rate was higher (39%) among the patients with
45 bacterial co-infections as compared to the group without co-infection (17%).

46 **Conclusions:** This study reveals that the rate of bacterial co-infections is significantly
47 increasing among COVID-19 patients and leading to increase in mortality. Systematic testing
48 of bacterial co-infections is therefore essential in COVID-19 patients for better clinical
49 outcomes and to reduce AMR.

50 **Keywords:** Bacterial co-infections, COVID-19, antimicrobial drug resistance.

51 **Introduction**

52 The human race has witnessed the emergence of four severe viral outbreaks in the last two
53 decades: the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) epidemic in
54 2002, the influenza A H1N1 pandemic in 2009, Middle East Respiratory Syndrome (MERS)
55 outbreak in 2012 and most recently the COVID-19 pandemic [1]. COVID-19 has emerged as
56 a global pandemic affecting millions of people world-wide and is proving to be a greater
57 danger than MERS and SARS Coronaviruses [2]. A plethora of symptoms have been
58 described in the past few months, clearly indicating that COVID-19 is a complex disease,
59 which in no way consists only of a respiratory infection. It presents with a variety of
60 unspecific symptoms so that the differential diagnosis encompasses a wide range of
61 infections. Most common symptoms of COVID-19 include respiratory symptoms like cough,
62 sputum, shortness of breath, fever; musculoskeletal symptoms like myalgia, joint pain,
63 headache, fatigue; enteric symptoms like abdominal pain, vomiting, diarrhea and
64 mucocutaneous symptoms (less common) [3]. Lung infections may progress in a few cases to
65 ARDS (Acute respiratory distress syndrome), shock and death. Cytokine storm, immune
66 dysregulation and various viral evasion mechanisms in the presence of various co-morbid
67 conditions has contributed to fatal outcomes in the COVID-19 patients [4].

68 Super-infection with bacterial pathogens has been identified in various viral respiratory
69 illnesses in the past and contributed to significant rates of morbidity and mortality [5-7].
70 Mortality has been reported to be as high as 20-30% in such cases of super-infection [7, 8].
71 Existence of bacterial co-pathogens in such respiratory patients leads to increased hospital
72 stay, greater chances of acquiring nosocomial infections and overall increase in cost of
73 hospital stay [9]. SARS-CoV-2 is a new virus with still limited knowledge about its
74 pathogenesis and clinical manifestations. Hence, there are several areas of knowledge gap
75 regarding this novel Coronavirus. One such area of potential research and studies is about the

76 co-existence, prevalence and incidence of bacterial pathogens in SARS-CoV-2[10, 11].
77 Various anti-viral and immuno-modulatory agents are being tried in COVID-19 hospitalized
78 patients, and several others are in experimental phase and under trials. Antibiotics are of no
79 use in such patients but are routinely prescribed due to the potential risk of secondary
80 bacterial infections [10]. Various studies have advocated the use of antibiotics in patients
81 suffering from respiratory symptoms of COVID-19 [12, 13]. However, such irrational and
82 unguided antibiotic use ultimately leads to emergence of antimicrobial resistance [11].
83 Hence, there is a dire need to study bacterial co-infections in COVID-19 patients and
84 understand the exact prevalence of such co-pathogens for the proper and rational use of
85 antibiotics. This study was planned with the aim to study the prevalence, demographic
86 parameters, risk factors, antibiotic sensitivity patterns and outcomes in hospitalized COVID-
87 19 patients with bacterial co-infections.

88 **Material and Methods**

89 **Place & Duration of Study**

90 The study was conducted at a tertiary care hospital of Northern India from March 2020 to
91 August 2020 (six months) during the COVID-19 pandemic.

92 **Study design**

93 During the time span of six months; a total of 1019 hospitalized COVID-19 patients were
94 included in the study. The patients were analyzed for the presence of bacterial co-infection as
95 determined by the presence of characteristic clinical features and culture positive blood,
96 respiratory, urine or pus/aspiration samples. The patients who were confirmed to have
97 bacterial co-infection were further analyzed. We collected following information on COVID-
98 19 patients with bacterial co-infection: demographic details of the admitted patients, presence
99 of co-morbidities (if any), date of admission and culture-positive results, day of

100 hospitalization on which bacterial culture was sent, antibiotic susceptibility profiles of the
101 bacterial isolates, length of hospital stay and clinical outcomes in the patients.

102 **Molecular testing for SARS CoV-2**

103 Two swabs, one oropharyngeal and the other deep nasal swab were collected from the
104 patients suspected of having SARS CoV-2 and transported in viral transport media (VTM) to
105 the laboratory. Viral RNA extraction was done using the QIAamp Viral RNA kit (Qiagen Inc.,
106 USA) according to the manufacturer's instructions. Real Time PCR was performed by
107 Applied Biosystems TaqPath COVID-19 kit (Thermo Fisher Scientific, USA) according to
108 the manufacturer's instructions.

109 **Bacterial culture & processing**

110 All the specimens (blood, respiratory, urine or pus /aspiration) were cultured on both
111 MacConkey and blood agar plates according to standard microbiological techniques. Further,
112 colonies were isolated and subcultures done accordingly. The bacterial isolates were first
113 identified using routine staining and biochemical tests [14]. The identities of bacteria were
114 further confirmed by MALDI-TOF MS and Vitek 2 system (Biomérieux Inc., France), an
115 automated identification and susceptibility testing system [15].

116 **Antibiotic susceptibility testing**

117 Antibiotic susceptibility testing was done by Kirby-Bauer's disk diffusion method on Muller
118 Hinton agar [16]. Results were interpreted based on Clinical and Laboratory Standards
119 Institute (CLSI) guidelines [17].

120 **Patient follow-up**

121 Organism profiles, sensitivity and other study parameters were kept in computer database
122 along with particulars of the patients. WHO classified the drug usage in hospitalized patients as
123 per the AWaRe criteria : Access, Watch and Reserve .This criteria was used to study the overall trend

124 of antibiotic usage in the patients. Follow up was planned in the suspected cases for any repeat
125 culture, outcomes & associated co-morbidities.

126 **Statistical Analysis**

127 The results were analyzed using the SPSS version 22 software (SPSS Inc., Chicago, IL,
128 USA). The frequencies are shown with 95% confidence intervals (95% CI). The Chi-square
129 and Mann-Whitney U test was used to analyse the statistically significant variables. The
130 statistically significant values were considered as p-value<0.05.

131

132 **Results**

133 A total of 1019 patients tested positive for COVID-19 in a span of six months and were
134 hospitalized at our COVID hospital. Out of these hospitalized COVID-19 patients, 5.2%
135 (n=53/1019) showed clinical signs of bacterial co-infection. Out of the total number of
136 patients having confirmed diagnosis of bacterial co-infection, a majority (66%; n=35/53)
137 acquired infections in the hospital (>48 hours of admission). The mean age of the patients
138 was 68 years (SD=57 ± 16) and it ranged from 8-75 years. Males comprised the majority of
139 the cases (61 %; n=32/53) as compared to females. Various co-morbidities in the patients
140 were also studied; hypertension (61%; n= 32/53) and diabetes mellitus (58%; n=31/53)
141 emerged as the most prevalent medical conditions. COPD/Asthma (27%; n=14/53), chronic
142 kidney disease (CKD) (23%; n=12/53) and chronic liver diseases (CLD) (19%; n=10/53)
143 were the other major co-morbidities among the COVID-19 patients.

144 **Etiology of the bacterial co-infections**

145 Among the various samples collected from COVID-19 patients suffering from co-infections,
146 blood was received from majority of the cases (37%; n=20/53). Urine (31%; n=16/53),
147 respiratory specimens (28%; n=14/53) and pus/aspirated fluid (4%; n=3/53) contributed for

148 the other bacteriological samples. Bacteremia was seen in majority of the COVID-19 positive
149 patients; followed by respiratory and urinary symptoms.

150 *E. coli* was the common isolate (21%; n=11/53), followed by *Pseudomonas aeruginosa*
151 (13.2%; n=7/53) and *Klebsiella spp.* (11.3%; n=6/53) among the Gram-negative organisms.
152 *Burkholderia cepacia*, *Stenotrophomonas maltophilia*, *Morganella morganii* and *Proteus*
153 *mirabilis* were isolated from one patient each. On the other hand; Coagulase-negative
154 *Staphylococci* (CONS) (18.8 %; n=10/53) and *Staphylococcus aureus* (17%; n=9/53) formed
155 the majority of isolates in Gram-positive organisms. Methicillin resistant *Staphylococcus*
156 *aureus* (MRSA) was seen in 4, Methicillin resistant coagulase-negative *Staphylococci*
157 (MRCONS) in 7, *Enterococcus spp.* in 5 and *Streptococcus spp.* in 1 case.

158 **Antibiotic sensitivity profile of bacterial isolates**

159 Antibiotic sensitivity testing revealed colistin (99%), imipenem (78%) and fosfomycin (95%)
160 (only in urinary isolates) as the most effective drugs against Gram-negative isolates whereas
161 vancomycin (100%), teicoplanin (99%) and doxycycline (71%) emerged as the most potent
162 drugs for Gram-positive bacterial infections. Detailed antibiotic sensitivity patterns for both
163 Gram-negative and Gram-positive isolates are summarized in Fig 1 & 2 respectively.

164 **Antibiotic usage**

165 As per the WHO criteria of AWaRe class of antibiotics, maximum antibiotics were prescribed from
166 the “watch” (48.02 %) and “reserve” categories (24.21 %). Only 20.7 % were given antibiotics from
167 the “access” category while 7.07 % of the patients were not recommended any antibiotics as depicted
168 in Fig 3 A & B.

169 **Clinical Outcomes**

170 The two groups of COVID-19 positive patients with and without bacterial co-infections were
171 compared in different clinical parameters and outcomes (Table 1). Patients with bacterial co-
172 infections belonged to the older age group as compared to the patients without bacterial co-
173 infections. No statistical significance was noted in terms of gender and other co-morbidities

174 like hypertension, diabetes, CKD, CLD, COPD/asthma on comparing between the two
175 groups. However; on comparing the clinical outcomes a significant difference was noted in
176 terms of in-patient mortality, number of patients requiring intubation, use of ventilators and
177 vasopressors. Patients with bacterial co-infections experienced a mortality rate of 39% as
178 compared to non-co-infection group (17%). The requirement of ventilators was higher in
179 patients with co-infection (35%) as compared to the non-co-infection group (21%).
180 Similarly, a higher percentage of patients with bacterial co-infections (37%) needed
181 intubation as compared to non-co-infection group (29%). Requirement of vasopressive drugs
182 was more in patients with bacterial co-infections (32%) as compared to the patients with co-
183 infection (14%).

184 **Discussion**

185 SARS CoV-2 is a newly emerging virus which has led to a global pandemic in a span of only
186 a few months. Its immunology, pathogenesis, clinical features and implications on the health
187 care settings are yet to be fully understood. There is a lack of clinical research and data on the
188 bacterial infections in these COVID-19 patients. Our study reported a bacterial co-infection
189 rate of 5.2 % which is very well in agreement to other similar studies done in various parts of
190 the world. A case series from Washington reported bacterial co-infection rate as 4.8%; while
191 some studies from China also reported a rate of 5-9% [18-24]. A meta-analysis done by
192 Lansbury et al., reported a bacterial co-infection rate of around 6.8% in hospitalized COVID-
193 19 cases [25].

194 The current study stressed the prevalence of bacterial co-infections to be higher among the
195 elderly age group (>65years). Several studies have emphasized the point of enhanced
196 pathogenesis of COVID-19 in the elderly age group. A lot of factors like decreased
197 mucociliary clearance, ciliary ultrastructural anomalies and immunosenescence play a key
198 role in this. “Inflamm-aeing “or increased release of inflammatory mediators and cytokines

199 leading to a cytokine surge is involved in tissue damage and multi-organ failure in such
200 patients [26]. A higher proportion of co-morbidities like diabetes and hypertension were seen
201 in the COVID cases in our study. This can be supported by the fact that diabetes mellitus
202 itself down-regulates the immune system by decreasing the effective T-cell and neutrophils
203 response [27]. It causes decreased phagocytosis, ineffective chemotaxis and decreased killing
204 of invading microbes by neutrophils and macrophages leading to increased susceptibility to
205 secondary bacterial infection [28]. Our study however failed to show any statistical
206 significance for the association of various co-morbidities to the increase in bacterial co-
207 infection rates among the COVID-19 cases. As such no role of increase in bacterial co-
208 infection rates per se have been described so far in this sub-group of patients.

209 Extensive search of literature revealed that there is no available report of high rate of
210 bacteremia and concurrent urinary tract infection (UTI) in COVID-19 patients. Ours is first
211 such study revealing bacteremia (37%) and UTIs (31%) as the most common co-infections in
212 COVID-19 patients. Other isolates were also isolated from respiratory (28%) and pus/aspirate
213 (4%) samples in the current study. *E. coli*, *Klebsiella* and *Pseudomonas* were the predominant
214 Gram-negative pathogens. One similar study in COVID-19 patients reported UTI in almost
215 half of the patients (57%) [29]. It also reported *E. coli* and *Enterobacter cloacae* as the most
216 commonly isolated pathogens. Another study by Lansbury et al., reported respiratory
217 pathogens such as *Mycoplasma pneumoniae*, *P. aeruginosa*, and *Haemophilus influenza* as
218 the most common isolates [25]. Increased prevalence of Gram-negative as well as Gram-
219 positive pathogens in the current study can be attributed to the immune dysregulation leading
220 to nosocomial infections and gut dysbiosis in COVID-19 positive patients. The inflammatory
221 mediators disrupt the intestinal permeability leading to the leakage of gut microbes and
222 associated metabolites into circulation. The leaked microbes and products via circulation
223 migrate to organs including lungs and produce bacteremia, UTIs and various other infections

224 [30]. Higher rates of diabetes in our group of patients also predispose to increase in secondary
225 bacterial infections including UTIs [31]. Immune dysregulation in SARS-CoV-2 infection is
226 characterized by lymphopenia, increased neutrophil–lymphocyte ratio, decreased NK-cells
227 and CD8+T-cell activity, decreased regulatory T-cells and increased CD4+ to CD8+ ratio.
228 Failure to eliminate virus due to inappropriate IFN response and decreased number and
229 function of CD8+ and NK-cells further leads to virus induced tissue damage and makes the
230 body more prone to secondary bacterial infections [31].

231 Colistin, Fosfomycin and Vancomycin proved to be some very effective drugs in treating
232 bacterial infections in COVID-19 positive cases. Administration of antibiotics in this co-
233 infection sub-group is vital to combat the ongoing bacterial infection in the form of blood
234 stream, urinary and respiratory infections as well as to avoid the increased chances of
235 acquiring secondary bacterial infections in such co-morbid patients. There was no significant
236 past history of any antibiotic or antimicrobial usage in these groups of patients. Providing the
237 correct and narrowed antibiotic coverage through proper antibiotic sensitivity testing will
238 look after the ill effects caused by broader empiric treatment in such cases. As already
239 highlighted in the study, most antibiotics prescribed were from the “watch” and “reserve”
240 categories of WHO AWaRe classification. Antibiotic stewardship programmes will lead the
241 path towards righteous treatment in COVID-19 infection group and will prevent the after
242 effects of long term treatment.

243 Discussing the clinical outcomes of our study, we noticed a much higher rate of in-patient
244 mortality in bacterial co-infection COVID-19 group (39%) as compared to the no infection
245 group (17%). A similar study by Alvaro et al., reported a mortality rate of 50% in COVID-19
246 patients with concomitant bacterial infection [29]. While a study from Wuhan, China also
247 reported similar mortality rates in this group of patients [20]. The increase in mortality rates
248 may also be attributed to the older population involved with bacterial co-infections along

249 with presence of other co-morbidities [32, 33]. The older population has weakened immune
250 system due to immunosenescence and hence succumbs to the infections more easily than the
251 younger ones. These people, therefore, more likely require interventions in the form of
252 intubation, mechanical ventilation and use of vasopressive drugs to improve the outcome and
253 increase their life expectancy. This fact was strongly suggested by our study where we
254 noticed statistical significance in these COVID-19 cases with bacterial co-infection for the
255 use of ventilator support, intubation and use of vasopressors as compared to the no infection
256 group.

257 A lot of aspects still need to be explored in the current COVID-19 pandemic situation for the
258 better understanding of its pathogenesis and control. Bacterial co-infections not necessarily
259 but certainly may increase the mortality rates in COVID-19 positive patients. Antibiotic
260 prescription as well as usage in this current situation must be properly guided through proper
261 culture reports, sensitivity testing and stringent antibiotic stewardship programmes.

262 **Declarations**

263 **Funding:** None

264 **Conflicts of interest/Competing Interests:** The authors declare that they have no conflict of
265 interest/competing interests.

266 **Ethics approval:** The study was approved by the institutional ethics committee of Sanjay
267 Gandhi Post Graduate Institute of Medical Sciences under reference number 2020-100-EMP-
268 EXP-16. Since, the study does not involve direct participation of human subjects so waiver of
269 consent was granted.

270 **Consent to participate:** Not applicable

271 **Availability of data and material:** The datasets used and/or analyzed during the current
272 study are available from the corresponding author on reasonable request.

273 **Author's contributions:** AP and CS conceptualized and supervised the study. AP, SS, SS
274 and NF collected the samples, performed the testing and drafted the manuscript. AG, UG,
275 SSP, AP and SS supervised the COVID-19 testing. AP and CS edited the manuscript.

276

277 REFERENCES

- 278 1. Guarner J. Three Emerging Coronaviruses in Two Decades. *Am J Clin Pathol.*
279 2020;153(4):420-1.
- 280 2. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus
281 2019) - recent trends. *Eur Rev Med Pharmacol Sci.* 2020;24(4):2006-11.
- 282 3. World Health Organization. Transmission of SARS-CoV-2: Implications for infection
283 prevention precautions. [https://www.who.int/publications/i/item/modes-of-transmission-](https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-COVID-19-implications-for-ipc-precaution-recommendations)
284 [of-virus-causing-COVID-19-implications-for-ipc-precaution-recommendations](https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-COVID-19-implications-for-ipc-precaution-recommendations)
285 (Accessed on September 10, 2020).
- 286 4. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of
287 COVID-19. *J Pharm Anal.* 2020;10(2):102-8.
- 288 5. Esper FP, Spahlinger T, Zhou L. Rate and influence of respiratory virus co-infection on
289 pandemic (H1N1) influenza disease. *J Infect.* 2011;63(4):260-6.
- 290 6. Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of
291 influenza and bacterial coinfection: a systematic review and meta-analysis. *Influenza*
292 *Other Respir Viruses.* 2016;10(5):394-403.
- 293 7. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR, 3rd, et al. Critical
294 illness from 2009 pandemic influenza A virus and bacterial coinfection in the United
295 States. *Crit Care Med.* 2012;40(5):1487-98.

- 296 8. Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell Jt, Mangino JE, et al.
297 Bacterial and viral co-infections complicating severe influenza: Incidence and impact
298 among 507 U.S. patients, 2013-14. *J Clin Virol.* 2016;80:12-9.
- 299 9. Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C,
300 et al. Community-acquired respiratory coinfection in critically ill patients with pandemic
301 2009 influenza A(H1N1) virus. *Chest.* 2011;139(3):555-62.
- 302 10. Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect
303 antimicrobial stewardship principles! *Clin Microbiol Infect.* 2020;26(7):808-10.
- 304 11. Cox MJ, Loman N, Bogaert D, O'Grady J. Co-infections: potentially lethal and
305 unexplored in COVID-19. *Lancet Microbe.* 2020;1(1):e11.
- 306 12. Gonzalez-Zorn B. Antibiotic use in the COVID-19 crisis in Spain. *Clin Microbiol Infect.*
307 2020. [https://doi: 10.1016/j.cmi.2020.09.055](https://doi.org/10.1016/j.cmi.2020.09.055).
- 308 13. Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al.
309 Recommendations for antibacterial therapy in adults with COVID-19 - an evidence
310 based guideline. *Clin Microbiol Infect.* 2021;27(1):61-6.
- 311 14. Collee JG, Miles RS, Watt B. Tests for identification of bacteria In: Collee JG, Fraser
312 AG, Marmion BP, Simmons A (eds): Mackie and McCartney Practical Medical
313 Microbiology, 14th ed, New York: Churchill –Livingstone, pp 131-50. 1996.
- 314 15. Ling TK, Tam PC, Liu ZK, Cheng AF. Evaluation of VITEK 2 rapid identification and
315 susceptibility testing system against gram-negative clinical isolates. *J Clin Microbiol.*
316 2001;39(8):2964-6.
- 317 16. Jan Hudzicki. 2009. Kirby-bauer disk diffusion susceptibility test protocol.
- 318 17. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial
319 Susceptibility Testing. CLSI supplement M100S. 27th ed. Wayne, PA: Clinical and
320 Laboratory Standards Institute; 2017.

- 321 18. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics
322 and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *Jama*.
323 2020;323(16):1612-4.
- 324 19. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of
325 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
326 retrospective, observational study. *Lancet Respir Med*. 2020;8(5):475-81.
- 327 20. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With
328 Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis*. 2020;71(15):769-77.
- 329 21. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of
330 refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis*. 2020. [https://doi:
331 10.1093/cid/ciaa270](https://doi.org/10.1093/cid/ciaa270).
- 332 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
333 infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-
334 506.
- 335 23. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
336 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
337 descriptive study. *Lancet*. 2020;395(10223):507-13.
- 338 24. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities:
339 A Multicenter Study of Clinical Features. *Am J Respir Crit Care Med*.
340 2020;201(11):1380-8.
- 341 25. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a
342 systematic review and meta-analysis. *J Infect*. 2020;81(2):266-75.
- 343 26. Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D'Agnano V, et al. COVID-19 and
344 the elderly: insights into pathogenesis and clinical decision-making. *Aging Clin Exp Res*.
345 2020;32(8):1599-608.

- 346 27. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review
347 of pathogenesis. *Indian J Endocrinol Metab.* 2012;16 Suppl 1(Suppl1):S27-36.
- 348 28. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two
349 epidemics. *Lancet Infect Dis.* 2009;9(12):737-46.
- 350 29. Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy R, 3rd, et al.
351 Bacterial infections and patterns of antibiotic use in patients with COVID-19. *J Med*
352 *Virol.* 2020. [https:// doi: 10.1002/jmv.26441](https://doi.org/10.1002/jmv.26441).
- 353 30. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity,
354 inflammation and intervention. *Nat Rev Immunol.* 2020;20(6):363-74.
- 355 31. de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de
356 Azevedo Silva J. Mechanism of inflammatory response in associated comorbidities in
357 COVID-19. *Diabetes Metab Syndr.* 2020;14(4):597-600.
- 358 32. Ambite I, Nagy K, Godaly G, Puthia M, Wullt B, Svanborg C. Susceptibility to Urinary
359 Tract Infection: Benefits and Hazards of the Antibacterial Host Response. *Microbiol*
360 *Spectr.* 2016;4(3).
- 361 33. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism
362 of cytokine storm in elderly adults with COVID-19 infection: the contribution of
363 "inflamm-aging". *Inflamm Res.* 2020;69(9):825-39.
- 364
- 365
- 366
- 367
- 368
- 369
- 370
- 371

372 Table 1: Comparison of co-morbidities and clinical outcomes in the two groups of COVID-
373 19 patients (with and without bacterial co-infections).

Clinical parameters	Cases with bacterial co-infection (n = 53, %)	Cases without bacterial co-infection (n=966, %)	P-values
Age (Mean ,Range in years)	68 (8 - 75)	59 (3-71)	0.007
<u>Gender</u>			
Males	32 (61)	609 (63)	0.019
Females	21 (39)	357 (37)	
<u>Co-morbidities</u>			
Hypertension	32(61)	628(65)	0.622
Diabetes Mellitus	31(58)	608(63)	0.588
COPD/Asthma	14(27)	280(29)	0.712
CKD	12(23)	174(18)	0.421
CLD	10(19)	203(21)	0.399
Heart diseases	5(10)	125(13)	0.512
Malignancies (Organ/Hematological)	7(14)	87 (9)	0.098
<u>Outcomes</u>			
In-patient mortality	21(39)	164(17)	<0.001
Use of Ventilators	18(35)	203(21)	<0.001
Use of vasopressive drugs	17(32)	135(14)	<0.001
Intubation	19(37)	251(29)	0.120

374

375

376

377


378

379

380

381


382



383

384 Fig 1: Antibiotic sensitivity pattern in Gram-negative isolates.

385




386

387 Fig 2: Antibiotic sensitivity pattern in Gram-positive isolates.


388

389

390



391



392 Fig 3: Illustration of antibiotics as per WHO Aware, Watch and Reserve (AWaRe)
 393 classification. (A) Total antibiotics usage in %. (B) Class of antibiotics usage in %.